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demonstrate the impact of population characteristics on
mean antipsychotic dose. We will compare results using
different techniques to adjust average dose for population
differences. Techniques presented will include stratifica-
tion, limiting study population variation, and various mul-
tivariate regression coding and modeling strategies. We
discuss which techniques provide the greatest generaliz-






WORKSHOP OBJECTIVE: Antibiotic resistance is an in-
creasing global problem and there is no doubt that it is
caused by antibiotic prescribing. Nonetheless, most pre-
scribing necessarily occurs at a time when it is uncertain
whether the patient has bacterial infection, never mind what
organism is causing the infection. The prescriber faces two
problems: 1) Which drug should I select in order to maxi-
mize this patient’s chance of recovery? (e.g., at what level of
trimethoprim resistance in Escherichia coli should I switch
to quinolones as my first line treatment for simple cystitis in
primary care?). 2) What impact does my choice of prescrib-
ing have on the prevalence of antibiotic resistance? (e.g., if I
recommend carbapenems for first-line treatment of sus-
pected intra-abdominal infection, will I be storing up future
trouble by increasing the prevalence of carbapenem resis-
tant bacteria in the hospital?). These two questions highlight
a conflict of interest that is at the heart of all healthcare de-
cision-making (Sabin, Br Med J 1998; 317:1002–4): the
competing duties of fidelity (to the individual patient) versus
stewardship (prudent allocation of scarce resources).
PARTICIPANTS WHO SHOULD ATTEND: Research-
ers and decision-makers with responsibility for antimi-
crobial prescribing. However, the issues raised are rele-
vant to the whole debate about priority setting.
The workshop will focus on two contrasting problems:
management of simple cystitis in primary care and man-
agement of intra-abdominal sepsis in hospitals. A generic
decision tree and influence diagram will be used as the
basis for discussion. Participants will be asked to identify
the key chance nodes that should influence decision-mak-
ing, and consider potential sources of information about
probabilities and utilities. The authors will share infor-
mation derived from two ongoing research projects.
WDM1
CURRENT COMPUTER SOFTWARE 
AND HARDWARE OPTIONS IN
PHARMACOECONOMICS: SPREADSHEETS, 
DECISION ANALYSIS, INTERNET, AND 
EDUCATIONAL TOOLS
McGhan WF
University of the Sciences in Philadelphia, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: At the end of this session,
participants will be able to compare and contrast various,
current software and hardware options for pharmacoeco-
nomics and outcomes research.
PARTICIPANTS WHO WOULD BENEFIT: This ses-
sion is intended for individuals who have a basic under-
standing of the concepts used in pharmacoeconomic
analyses who wish to learn more about computer soft-
ware and hardware options.
Pharmacoeconomic analysis software programs should al-
low data and results to be examined from different policy
perspectives: 1) patient, 2) provider, 3) hospital, 4) payer,
and 5) society. Software models should also allow the as-
sessment of the healthcare interventions or services from
different quantitative perspectives: 1) cost of illness, 2)
cost-minimization, 3) cost-benefit, 4) cost-effectiveness,
and 5) cost-utility. Decision trees and sensitivity analysis
software will be reviewed. Programming options include
spreadsheet macros, visual basic, and Web page authoring
tools. Software programs will be demonstrated that can be
utilized on various hardware platforms including desk-
tops, laptops, and remote handhelds. Software applica-
tions can assist in analyzing data, present findings, or edu-
cate providers and patients. More software is becoming
available that facilitates assessment and incorporation of
patient preferences and quality of life scores into therapy
decision-making for treatment protocol development and
interfacing at the patient’s bedside. Questions that should
be asked in evaluating software include: How much of the
model is built on rigorous clinical trial data? Has the soft-
ware been peer reviewed and field tested? Are any ques-
tionnaires valid and reliable? Is the information well ref-
erenced? Can sensitivity and incremental analyses be
performed? Software and hardware options will be dem-
onstrated. Pros and cons of diverse analytical and soft-
ware approaches will be examined.
WMM1
IS THE CURRENT RELIANCE ON THE
MARKOV ASSUMPTION IN ECONOMIC
MODELS JUSTIFIED?
Caro JJ, Huybrechts KF
Caro Research, Boston, MA, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to demonstrate why the willingness to rely on the
Markov restriction in economic models may not be justi-
fied and to suggest alternative approaches.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers involved in the development of health economic mod-
els, as well as those responsible for evaluating models.
Markov processes were first described by the Russian
mathematician Markov at the beginning of this century.
His intent was to generalize classical properties of se-
quences of independent random variables to sequences
not fulfilling the independence assumption. A Markov
